Final Height after Growth Hormone Therapy in Peripubertal Boys with a Subnormal Integrated Concentration of Growth Hormone

Zadik, Zvi; Ulman, Mira; Landau, H

doi:10.1159/000182300

Cited by 41 publications

(29 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings suggest that the average result of 6 or more years daily rhGH injections is about 0.4 SD, which is 2.4 cm. These results are not necessarily in conflict with the results of a study (Zadik et al, 1992b) showing a positive effect of GH on final height in 17 peripubertal boys with ISS and a subnormal integrated concentration of GH, as in our study also children with a low integrated concentration of GH did better than the others. Our data are in line with those of a recent collaborative study on children with variable endogenous GH secretion (Guyda, 1994).…”

Section: Dlscursloncontrasting

confidence: 92%

Long‐term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues

Wit

Boersma

Keizer-Schrama³

et al. 1995

Clinical Endocrinology

View full text Add to dashboard Cite

Summary BACKGROUND AND OBJECTIVE Growth hormone treatment In children with Idiopathic short stature (ISS) leads to growth acceleration in the first years, but the effect on final height is still poorly documented. We therefore studied the long‐term effect of GH therapy in children with Idiopathic short stature. DESIGN We have treated 27 prepubertal children with ISS with recombinant human GH (rhGH) in an initial dosage of 2 IU/m2 body surface/day subcutaneously, which was doubled either after the first year if the height velocity increment was less than 2 cm/year, or thereafter if height velocity fell below the P50 for bone age. Growth and bone maturation of the treatment group (ISS group, n= 21) were compared to those of an untreated control group with ISS (ISS controls, n= 27) and of a group of rhGH treated children with isolated GH deficiency (GHD group, n= 7). RESULTS In 9 patients of the ISS group still on treatment, height standard deviation score (HSDS) for chronological age increased from −3.8±0.7 to −2.3±0.9 (mean±standard deviation) over 6 years, while in matched ISS controls HSDS for age did not change. HSDS for age in the GHD group increased from −3.9±0.6 to −1.8±0.7 after 4 years, significantly more than the ISS group. Bone maturation was accelerated In the ISS and GHD groups. HSDS for bone age and predicted adult height did not change in either group. Final height in 12 children of the ISS group was −2.6±1.0 SDS. In the untreated controls final height was similar. A low integrated GH concentration over 24 hours, a low GH peak to provocative stimuli, and minimal initial BA delay predicted a favourable outcome. CONCLUSION rhGH treatment In this group of children with Idiopathic short stature did not increase average final height. Part of the heterogeneity of the response can be attributed to the variation in endogenous GH secretion and initial bone age delay.

show abstract

Section: Dlscursloncontrasting

confidence: 92%

Long‐term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues

Wit

Boersma

Keizer-Schrama³

et al. 1995

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…The Zadik non-randomised study, 53 which considered boys with subnormal IC-GH, found a significantly greater final height in the GHtreated group compared with untreated controls: 164.5 ± 3.9 cm versus 157.6 ± 4.5 cm, respectively (p < 0.04). The Hindmarsh and Brook study 54 found an average height increase in GH-treated children of 2.8 cm in boys and 2.5 cm in girls.…”

Section: Final Heightmentioning

confidence: 97%

“…Two non-randomised studies 53,54 reporting final height met the inclusion criteria for the review (Tables 33 and 34, with details in appendix 20).…”

Section: Studies Reporting Final Heightmentioning

confidence: 99%

“…54 The other study 53 was a small prospective cohort study with concurrent controls, and included boys with ISS and a subnormal integrated concentration of GH (IC-GH < 3.2 µg/l). These children are considered by some clinicians to be a separate diagnostic category.…”

Section: Studies Reporting Final Heightmentioning

confidence: 99%

“…In the other study, 53 objective criteria for outcomes and inclusion were used, and the two groups were comparable.…”

Section: Studies Reporting Final Heightmentioning

confidence: 99%

See 2 more Smart Citations

Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation

Bryant

Cave

Mihaylova

et al. 2002

Health Technol Assess

139

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Technology assessment reports are completed in a limited time to inform the appraisal and guidance development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisals and guidance produced by NICE are informed by a wide range of sources.The research reported in this monograph was funded as project number 00/21/01.The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors. Criteria for inclusion in the HTA monograph seriesRe...

show abstract

Effect of Growth Hormone Therapy on Height in Children With Idiopathic Short Stature

Finkelstein¹,

Imperiale²,

Speroff³

et al. 2002

Arch Pediatr Adolesc Med

195

129

View full text Add to dashboard Cite

Treatment with GH results in short-term increases in growth for children with idiopathic short stature, and long-term GH can increase adult height. These results are fundamental to decisions about GH use and raise questions about the goals of treatment. Use of GH for idiopathic short stature in clinical practice will depend on its efficacy in promoting growth and the value of this effect to families, physicians, and third-party payers.

show abstract

Final Height after Growth Hormone Therapy in Peripubertal Boys with a Subnormal Integrated Concentration of Growth Hormone

Cited by 41 publications

References 8 publications

Long‐term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues

Long‐term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues

Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation

Effect of Growth Hormone Therapy on Height in Children With Idiopathic Short Stature

Contact Info

Product

Resources

About